IO-108,pembrolizumab,cemiplimab 
Immune-Onc Therapeutics,Merck,Regeneron
['aml,(-streamline),(-seamless),(-kamloops),(-dreamlike)', 'aml,(-streamline),(-seamless),(-kamloops),(-latamleaders)', 'io-108']
sfbn feed: immune-onc therapeutics to present encouraging phase 1 data for io-108 at aacr annual meeting 2023: palo alto, calif.--(business wire)-- #aml--immune-onc therapeutics, inc. ( immune-onc ), a ... #bayarea #biotech 
San Francisco Biotechnology News and Events, follow jobs at @sfbnjobs